OTCPK:WXXWY (China)
Business Description
WuXi Biologics (Cayman) Inc
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
Compare
Compare
Traded in other countries / regions
1FW2.Germany
•
02269.Hong Kong
•
2269.Mexico
•
WXXWY.USA
Description
WuXi Biologics ("WuXi") is a contract development and manufacturing organization, or "CDMO," for biologic drugs. It was founded in 2010 as part of WuXi AppTec and listed on the Hong Kong Stock Exchange in 2017. WuXi provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others. It does not conduct clinical trials.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.59 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 1.07 | |||||
| Interest Coverage | 88.39 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 13.76 | |||||
| Beneish M-Score | -1.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 57.4 | |||||
| 3-Year EBITDA Growth Rate | 70.1 | |||||
| 3-Year EPS without NRI Growth Rate | 73 | |||||
| 3-Year FCF Growth Rate | -40.6 | |||||
| 3-Year Book Growth Rate | 55.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 29.87 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 36.79 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.77 | |||||
| 9-Day RSI | 40.87 | |||||
| 14-Day RSI | 44.23 | |||||
| 6-1 Month Momentum % | 31.81 | |||||
| 12-1 Month Momentum % | -38.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.16 | |||||
| Cash Ratio | 1.35 | |||||
| Days Inventory | 99 | |||||
| Days Sales Outstanding | 97.42 | |||||
| Days Payable | 39.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.9 | |||||
| Operating Margin % | 33.62 | |||||
| Net Margin % | 32.88 | |||||
| ROE % | 11.88 | |||||
| ROA % | 8.77 | |||||
| ROIC % | 12.61 | |||||
| ROC (Joel Greenblatt) % | 20.74 | |||||
| ROCE % | 12.37 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 75.69 | |||||
| Forward PE Ratio | 57.8 | |||||
| PE Ratio without NRI | 75.69 | |||||
| Price-to-Owner-Earnings | 312.11 | |||||
| PEG Ratio | 1.15 | |||||
| PS Ratio | 25.02 | |||||
| PB Ratio | 7.63 | |||||
| Price-to-Tangible-Book | 8.19 | |||||
| Price-to-Operating-Cash-Flow | 74.89 | |||||
| EV-to-EBIT | 59.29 | |||||
| EV-to-Forward-EBIT | 50.07 | |||||
| EV-to-EBITDA | 59.29 | |||||
| EV-to-Forward-EBITDA | 43.75 | |||||
| EV-to-Revenue | 23.21 | |||||
| EV-to-Forward-Revenue | 16.68 | |||||
| EV-to-FCF | -77.89 | |||||
| Price-to-Projected-FCF | 90.05 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.01 | |||||
| Price-to-Graham-Number | 5.25 | |||||
| Price-to-Net-Current-Asset-Value | 31.6 | |||||
| Earnings Yield (Greenblatt) % | 1.69 | |||||
| Forward Rate of Return (Yacktman) % | 19.27 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with OTCPK:WXXWY
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,609.572 | ||
| EPS (TTM) ($) | 0.241 | ||
| Beta | 0.65 | ||
| Volatility % | 40.42 | ||
| 14-Day RSI | 44.23 | ||
| 14-Day ATR ($) | 0.779634 | ||
| 20-Day SMA ($) | 19.204125 | ||
| 12-1 Month Momentum % | -38.4 | ||
| 52-Week Range ($) | 10.5 - 33.32 | ||
| Shares Outstanding (Mil) | 2,107.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WuXi Biologics (Cayman) Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||